BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Japanese BAY80-6946 Monotherapy Phase I Study
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: BAY80-6946
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT01404390
Wellnara Post-marketing Surveillance in Japan
Completed
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Drug: E2/LNG oral (Wellnara, BAY86-5029)
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 411
- Registration Number
- NCT01401114
Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan
Completed
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Drug: E2 transdermal (Julina, BAY86-5435)
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 148
- Registration Number
- NCT01397955
LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: LNG-IUS (BAY 86-5028)Drug: 68 mg etonorgestrel implant for subdermal use (Nexplanon)
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 766
- Registration Number
- NCT01397097
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting
Completed
- Conditions
- Primary Hypertension
- Interventions
- Drug: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2012-07-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1586
- Registration Number
- NCT01392534
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64
- Registration Number
- NCT01392521
Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 118
- Registration Number
- NCT01389271
Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium
Phase 3
Completed
- Conditions
- Pain, Postoperative
- Interventions
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 300
- Registration Number
- NCT01389284
A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT01388153
Kogenate FS Regulatory Post-Marketing Surveillance
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64
- Registration Number
- NCT01386268
© Copyright 2025. All Rights Reserved by MedPath